COAG — Hemab Therapeutics Holdings, Inc.

COAGHemab Therapeutics Holdings, Inc.

NAS · US · Healthcare · Biotechnology · hemab.com

27.58USD+6.55%Mkt Cap: 1.29B USDP/E: —Last update: 2026-05-26

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States …

Industry Peers

Biotechnology

VRTX

Vertex Pharmaceuticals Incorporated

Regeneron Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

39.41BUSDP/E 74.0

RVMD

Revolution Medicines, Inc.

Indicators:|

Key Statistics

Company

Market Cap1.29B USD

Enterprise Value—

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-63.91M USD

Revenue/Share—

Last Price27.58 USD

Fiscal Year EndDec 2025

MR Quarter—

Employees59

CountryUS

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B-0.14

EPS (TTM)-2.33

EPS (Forward)—

52W Range

23.0034% of range36.61

52W High36.61 USD

52W Low23.00 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE36.18%

ROA-32.81%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-61.48M USD

CapEx (TTM)16.00K USD

FCF Margin—

FCF Yield-3.08%

Net Debt—

Net Debt/EBITDA—

Balance Sheet

Debt/Equity-0.01

Current Ratio18.03

Quick Ratio17.62

Book Value/Sh-186.7180 USD

Cash/Share—

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.46.71M

Float456.13K

Insiders10.78%

Institutions59.89%

Technical

SMA 5026.76 (+3.1%)

SMA 20026.76 (+3.1%)

Beta—

S&P 52W Chg28.31%

Avg Vol (30d)466.48K

Avg Vol (10d)171.37K

Technical Indicators

RSI (14)—

MACD—

MACD Signal—

MACD Hist.—

BB Upper—

BB Middle—

BB Lower—

BB Width—

ATR (14)—

Vol Ratio (20d)—